ABCL: Menopause Phase 2 Progress Will Support Future Margin Expansion

The analyst price target on AbCellera Biologics has been raised by $1. Analysts cite updated fair value estimates, a slightly lower discount rate, revised revenue growth expectations, and a very large projected future P/E multiple as key drivers of the change.

Analyst Commentary

Bullish Takeaways

Bullish analysts point to updated fair value work and a slightly lower discount rate as support for a higher price target, which lifts their view of AbCellera Biologics' long term valuation potential.
Recent initiations with a bullish view frame the company as having a profile that some analysts see as attractive compared with certain peers, which they link to longer term growth prospects rather than near term results.
The use of a very large projected future P/E multiple in some models reflects confidence in the company’s ability to build earnings power over time, even if current financials are not yet aligned with that multiple.
Bullish analysts highlight that revised revenue growth expectations underpin their optimism, suggesting that, if the company executes on its pipeline and partnerships, the higher valuation case could remain intact.

Bearish Takeaways

Some cautious analysts focus on execution risk around those higher revenue expectations, noting that if milestones slip or programs underperform, the current valuation assumptions could look stretched.
The reliance on a very large future P/E multiple raises concern for more conservative investors, since even modest changes in earnings or timing could have an outsized impact on valuation.
Comparisons to other companies in the space, including those viewed as less attractive, underline the risk that sentiment can shift quickly if AbCellera Biologics does not meet the growth trajectory embedded in analyst models.
Cautious views also emphasize that fair value estimates are sensitive to discount rates and other model inputs, so any change in perceived risk or project timing could weigh on future target revisions.

What's in the News

AbCellera reported Q1 2026 revenue that was nearly double the prior year period, ahead of expectations, alongside positive interim Phase 1 data for lead antibody ABCL635, according to Zacks (May 22, 2026).
Interim Phase 1 results for ABCL635, a potential first in class NK3R antibody for menopause related hot flashes, supported advancement into Phase 2, with a key efficacy readout flagged for Q3 2026, per Zacks (May 22, 2026).
Analysts at firms including Stifel and Cantor Fitzgerald raised price targets and earnings estimates by more than 25% over the past quarter, and Zacks currently assigns AbCellera a Rank #2 (Buy), placing it among its favored earnings momentum stocks in Medical, Biomedical and Genetics (May 22, 2026).
AbCellera shares were reported to be up about 38% over the past month and 80.4% year to date, with technical traders highlighting a golden cross where the 50 day moving average moved above the 200 day moving average, per Zacks (May 22, 2026).
The company is shifting focus toward proprietary drug development, with ABCL635 in a double blind Phase 2 trial for menopause related vasomotor symptoms and plans, if results are successful, to pursue a Phase 3 trial by 2027 and explore oncology associated hot flashes, as well as advance two additional candidates into the clinic by 2027; AbCellera also appointed experienced drug developer Dr. Victor Sandor to its Board of Directors (January 1, 2025).

Valuation Changes

Fair Value: The updated fair value estimate has risen slightly from $9.83 to $10.43.
Discount Rate: The applied discount rate has edged lower from 7.82% to 7.67%, indicating a modest reduction in assumed risk.
Revenue Growth: Modeled revenue growth has shifted from an expected 52.74% increase to a 19.79% decline, representing a very sharp swing in the outlook for top line expansion.
Profit Margin: The assumed profit margin has eased slightly from 15.74% to 15.57%, indicating a marginally more conservative view on future profitability.
Future P/E: The projected future P/E multiple has moved from about 187x to roughly 665x, which makes the valuation far more sensitive to execution and the timing of earnings.

6 views

Key Takeaways

Transition to a clinical-stage biotech and internal programs could drive revenue through milestone fees and royalty payments from new molecules.
Integrated clinical manufacturing capabilities will likely boost efficiency and margins, while strong liquidity supports long-term pipeline development.
High R&D expenses and competition pose challenges for AbCellera Biologics' revenue growth, while uncertainties in asset development may impact future financial stability.

Catalysts

About AbCellera Biologics

Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.What are the underlying business or industry changes driving this perspective?

The initiation of Phase I clinical trials for ABCL635 and ABCL575, with promising differentiation factors such as a unique dosing regimen and improved safety profile for ABCL635, is expected to position the company to capture a significant market opportunity in an underserved area, potentially boosting future revenue.
AbCellera's transition from a platform company to a clinical-stage biotech, along with the development of internal programs, suggests a shift towards generating revenue from downstream milestone fees and royalty payments as new molecules are expected to reach the clinic.
The completion of AbCellera's integrated clinical manufacturing capabilities by the end of 2025 is likely to enhance operational efficiency and reduce COGS, potentially improving net margins as the company begins utilization of these capabilities.
Financial backing with over $630 million in liquidity and additional funding commitments provides AbCellera with the necessary resources to support long-term pipeline development, enhancing potential future earnings through successful commercialization of their clinical candidates.
Potential future partnerships and licensing based on AbCellera’s T-cell engager platform could offer additional revenue streams and drive growth, particularly if the platform successfully demonstrates efficacy and safety for solid tumor treatments, an area with high unmet medical need.

AbCellera Biologics Earnings and Revenue Growth

AbCellera Biologics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming AbCellera Biologics's revenue will decrease by 19.8% annually over the next 3 years.
Analysts are not forecasting that AbCellera Biologics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate AbCellera Biologics's profit margin will increase from -181.7% to the average US Life Sciences industry of 15.6% in 3 years.
If AbCellera Biologics's profit margin were to converge on the industry average, you could expect earnings to reach $6.4 million (and earnings per share of $0.02) by about June 2029, up from -$144.0 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 666.6x on those 2029 earnings, up from -11.2x today. This future PE is greater than the current PE for the US Life Sciences industry at 38.4x.
Analysts expect the number of shares outstanding to grow by 2.19% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.67%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Despite advances like ABCL635, there is risk related to target engagement in humans, with no guarantee the promising preclinical results will translate to clinical efficacy. This could impact potential revenue from ABCL635 if it fails to achieve market viability.
The company's net loss widened from $41 million in Q1 2024 to $46 million in Q1 2025, and decreasing revenue from partner-initiated programs poses risks to future earnings stability.
Competition from small molecules fezolinetant and elinzanetant, which are already established in the market, poses commercial challenges for ABCL635, potentially impacting market share and revenue growth.
Despite significant cash reserves, ongoing high R&D expenses, with $43 million spent in Q1 2025, emphasize the company's need for continual investment, raising concerns about future net margins if investments don't yield expected returns.
Uncertainties in the progress of partnered assets, like the paused development of NovaRock molecules, could limit potential milestone payments and royalty revenues, affecting future financial performance.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $10.43 for AbCellera Biologics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $13.0, and the most bearish reporting a price target of just $7.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $40.9 million, earnings will come to $6.4 million, and it would be trading on a PE ratio of 666.6x, assuming you use a discount rate of 7.7%.
Given the current share price of $5.3, the analyst price target of $10.43 is 49.2% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on AbCellera Biologics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Phase I Trials And Manufacturing Will Unlock Pipeline Potential